Evotec SE (NASDAQ:EVO – Get Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 195,500 shares, a growth of 23.5% from the May 31st total of 158,300 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 146,100 shares, the short-interest ratio is currently 1.3 days.
Analysts Set New Price Targets
EVO has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Evotec in a research report on Thursday, May 23rd. Deutsche Bank Aktiengesellschaft upgraded Evotec from a “hold” rating to a “buy” rating in a research report on Friday, April 12th.
Check Out Our Latest Research Report on Evotec
Institutional Inflows and Outflows
Evotec Trading Up 1.9 %
Evotec stock traded up $0.09 during midday trading on Tuesday, reaching $4.95. The stock had a trading volume of 31,345 shares, compared to its average volume of 114,430. The firm’s fifty day simple moving average is $4.91 and its two-hundred day simple moving average is $7.07. Evotec has a twelve month low of $3.94 and a twelve month high of $13.49. The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Articles
- Five stocks we like better than Evotec
- How to Calculate Retirement Income: MarketBeat’s Calculator
- RXO Shares Surge Following New Acquisition Deal
- Using the MarketBeat Stock Split Calculator
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.